Association of Endocrinologists on Clinical Care Team With Sodium-Glucose Cotransporter 2 Inhibitor Prescription for People With Type 2 Diabetes After Coronary Artery Bypass Grafting: A Two-Center Study.

Q2 Medicine

Clinical Diabetes Pub Date : 2025-03-06 eCollection Date: 2025-01-01 DOI:10.2337/cd24-0107

Yangtian Yi, Nicolas Kumar, Matthew R Smith, Ariel Mueller, Timothy Houle, Arminder Jassar, Lauren J Cornella, Robert B Schonberger, Amit Bardia

引用次数: 0

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are underutilized in people with type 2 diabetes after coronary artery bypass grafting (CABG). This study investigated the association of the presence of an endocrinologist on treatment teams with SGLT2 inhibitor prescription in patients with type 2 diabetes after CABG. The presence of an endocrinologist was associated with a more than twofold increase in the odds of obtaining an SGLT2 inhibitor prescription. This finding suggests that involving endocrinologists in these patients' postoperative care may improve prescription and use of SGLT2 inhibitors after CABG.

查看原文本刊更多论文

2型糖尿病患者冠状动脉搭桥术后钠-葡萄糖共转运蛋白2抑制剂处方与内分泌学家临床护理团队的关联：一项双中心研究

钠-葡萄糖共转运蛋白2 （SGLT2）抑制剂在冠状动脉搭桥术（CABG）后2型糖尿病患者中的应用不足。本研究调查了2型糖尿病患者CABG后治疗团队中内分泌学家的存在与SGLT2抑制剂处方的关系。内分泌学家的存在与获得SGLT2抑制剂处方的几率增加两倍以上相关。这一发现表明，让内分泌学家参与这些患者的术后护理可能会改善CABG后SGLT2抑制剂的处方和使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Diabetes Medicine-Internal Medicine

CiteScore

4.30

自引率

0.00%

发文量

期刊介绍： The mission of Clinical Diabetes is to provide primary care providers and all clinicians involved in the care of people with diabetes with information on advances and state-of-the-art care for people with diabetes. Clinical Diabetes is also a forum for discussing diabetes-related problems in practice, medical-legal issues, case studies, digests of recent research, and patient education materials.